Table 5.

Overall and subgroup prevalence of BULIMIA NERVOSA

	Number of studies (number of datasets)	n	Number of cases	I2 (p-value)	Prevalence (%)	95% CI	p-value
Lifetime prevalence	19 (20)	198,102	1151	98.9 (< 0.001)	(R) 0.63	0.33–1.02	–
DSM-IV	13 (13)	135,624	855	99.2 (< 0.001)	(R)0.57	0.21–1.12	0.221
DSM-5	2 (2)	39,286	196	99.5 (< 0.001)	(R)1.41	0.00–6.30
Studies conducted 1990–1999	3 (3)	12,615	66	60.8 (< 0.001)	(R) 0.53	0.06–1.49	0.476
Studies conducted 2000–2009	9 (10)	100,529	617	99.0 (< 0.001)	(R) 0.41	0.10–0.93
Studies conducted 2010–2017	6 (6)	82,843	445	99.3 (< 0.001)	(R) 1.08	0.33–2.25
Studies in Western countries	13 (13)	110,715	990	97.9 (< 0.001)	(R) 1.02	0.63–1.49	< 0.001
Studies in Asia	6 (7)	79,635	79	97.3 (< 0.001)	(R) 0.14	0.02–0.36
Males	12 (12)	46,760	178	95.7 (< 0.001)	(R) 0.38	0.15 -0.73	0.008
Females	12 (12)	49,917	596	97.0 (< 0.001)	(R) 1.22	0.69–1.88
12-month prevalence	13 (13)	146,373	408	97.4 (< 0.001)	(R) 0.31	0.15–0.53	–
DSM-IV	11 (11)	117,896	380	97.7 (< 0.001)	(R)0.29	0.12–0.54	–
DSM-5	1 (1)	36,309	44	–	0.14	–
Studies conducted 1990–1999	3 (3)	12,615	42	96.6 (< 0.001)	(R) 0.29	0.00–1.11	0.942
Studies conducted 2000–2009	6 (6)	57,290	225	95 (< 0.001)	(R) 0.28	0.10–0.54
Studies conducted 2010–2017	4 (4)	76,468	141	98.6 (< 0.001)	(R) 0.41	0.10–0.94
studies in Western countries	10 (10)	102,225	324	94.5 (< 0.001)	(R) 0.33	0.19–0.51	0.294
Studies in Asia	3 (3)	36,396	46	98.6 (< 0.001)	(R) 0.27	0.00–1.20
Males	8 (8)	40,488	52	90.0 (< 0.001)	(R) 0.09	0.02–0.22	0.113
Females	8 (8)	42,741	168	94.5 (< 0.001)	(R) 0.29	0.10–0.57
4-week prevalence	5 (5)	53,064	30	94.8 (< 0.001)	(R) 0.07	0.00–0.23	—